NDA 017989 · Pfizer
Hemabate
Carboprost Tromethamine · Injection
NovelLast checked: Nov 20, 2026Latest source record: Jun 19, 2015 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1979
Jan 9, 1979
Approved uses
1
Original approval plus efficacy supplements
Registered trials
9
0 Phase 3, 1 recruiting
FAERS reports
734
702 serious, 2 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNINGS HEMABATE Sterile Solution (carboprost tromethamine), like other potent oxytocic agents, should be used only with strict adherence to recommended dosages. HEMABATE should be used by medically trained personnel in a hospital which can provide immediate intensive care and acute surgical facilities.
What it is approved for
From the label in effect Mar 30, 2026.
INDICATIONS AND USAGE HEMABATE Sterile Solution is indicated for aborting pregnancy between the 13th and 20th weeks of gestation as calculated from the first day of the last normal menstrual period and in the following conditions related to second trimester abortion: 1. Failure of expulsion of the fetus during the course of treatment by another method; 2. Premature rupture of membranes in intrauterine methods with loss of drug and insufficient or absent uterine activity; 3. Requirement of a repeat intrauterine instillation of drug for expulsion of the fetus; 4. Inadvertent or spontaneous rupture of membranes in the presence of a previable fetus and absence of adequate activity for expulsion. HEMABATE is indicated for the treatment of postpartum hemorrhage due to uterine atony which has not responded to conventional methods of management. Prior treatment should include the use of intravenously administered oxytocin, manipulative techniques such as uterine massage and, unless contraindicated, intramuscular ergot preparations. Studies have shown that in such cases, the use of HEMABATE has resulted in satisfactory control of hemorrhage, although it is unclear whether or not ongoing or delayed effects of previously administered ecbolic agents have contributed to the outcome. In a high proportion of cases, HEMABATE used in this manner has resulted in the cessation of life threatening bleeding and the avoidance of emergency surgical intervention.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 9, 1979 Original approval · Type 1 - New Molecular Entity
1 products under this application
- HEMABATE · CARBOPROST TROMETHAMINE EQ 0.25MG BASE/ML · INJECTABLE, INJECTION · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Carboprost Tromethamine" as an intervention, any sponsor and status, largest first.
Dongyu WangAcademic, hospital or other
NCT02861482 · 472 participants · Start Jan 2015 · Primary completion Mar 2016
Drug: Oxytocin; Hemabate and 2 more · For: Postpartum Hemorrhage
Sites: Guangzhou, China
- Misoprostol Versus Active Management of Labour in CSPivotal-lookingCompleted
Aljazeera HospitalAcademic, hospital or other
NCT03390010 · 300 participants · Start Dec 28, 2017 · Primary completion Feb 28, 2018
Drug: Misoprostol + syntocinon and using extra uterotonic drugs when needed ; methergine; Syntocinon and using extra uterotonic drugs when needed ; methergine carboprost · For: Cesarean Section
Sites: Giza, Egypt
- The Time Point of Carboprost Methylate Administration and Perioperative ComplicationsPivotal-lookingCompleted
Peking Union Medical College HospitalAcademic, hospital or other
NCT05834361 · 120 participants · Start Jan 1, 2022 · Primary completion Dec 31, 2022
Drug: early vaginal administration of carboprost methylate; delayed vaginal administration of carboprost methylate · For: Artificial Abortion, PONV(Post Operative Nausea and Vomiting)
Sites: Beijing, China
- Comparison of IV Ergonovine With IM Carboprost, With Oxytocin IV, During Cesarean Section for Failure to ProgressPivotal-lookingCompleted
Samuel Lunenfeld Research Institute, Mount Sinai HospitalAcademic, hospital or other
NCT01869556 · 105 participants · Start Jun 4, 2013 · Primary completion Jul 8, 2019
Drug: Oxytocin; Ergot and 1 more · For: Postpartum Hemorrhage
Sites: Toronto, Canada
- Second-Line Uterotonics in Postpartum Hemorrhage: A Randomized Clinical TrialPivotal-lookingCompleted
Brigham and Women's HospitalAcademic, hospital or other
NCT03584854 · 100 participants · Start Mar 1, 2019 · Primary completion May 22, 2022
Drug: 15-methyl prostaglandin F2α; Methylergonovine Maleate · For: Postpartum Hemorrhage; Uterine Atony
Sites: Boston, Massachusetts
Brigham and Women's HospitalAcademic, hospital or other
NCT01549223 · 60 participants · Start Apr 2011 · Primary completion Jan 2012
Drug: Oxytocin Infusion; Oxytocin Bolus · For: Uterine Atony; Hypotension
Sites: Boston, Massachusetts
Samuel Lunenfeld Research Institute, Mount Sinai HospitalAcademic, hospital or other
NCT00989027 · 56 participants · Start Jun 2007 · Primary completion Aug 2013
Drug: Oxytocin; Ergonovine and 3 more · For: Postpartum Hemorrhage
Sites: Toronto, Canada
Samuel Lunenfeld Research Institute, Mount Sinai HospitalAcademic, hospital or other
NCT06285409 · 32 participants (planned) · Start Apr 4, 2024 · Primary completion Dec 2026
Drug: Carbetocin; Oxytocin and 4 more · For: Postpartum Hemorrhage
Sites: Toronto, Canada
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- vomiting224
- nausea199
- diarrhoea144
- off label use144
- abdominal pain upper102
- chest discomfort95
- abdominal pain71
- abdominal discomfort69
- dyspnoea67
- blood pressure increased63
- hyperhidrosis41
- palpitations41
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 3 |
| 2005 | 4 |
| 2006 | 1 |
| 2007 | 2 |
| 2009 | 5 |
| 2010 | 2 |
| 2011 | 3 |
| 2012 | 5 |
| 2013 | 7 |
| 2014 | 3 |
| 2015 | 4 |
| 2016 | 9 |
| 2017 | 7 |
| 2018 | 12 |
| 2019 | 19 |
| 2020 | 33 |
| 2021 | 90 |
| 2022 | 138 |
| 2023 | 131 |
| 2024 | 121 |
| 2025 | 83 |
| 2026 | 52 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Second-Line Uterotonics for Uterine Atony: A Randomized Controlled Trial.
Cole NM, Kim JJ, Lumbreras-Marquez MI, et al. · Obstet Gynecol 2024 · Randomized Controlled Trial, Multicenter Study
- A Comparison of Dexmedetomidine and Midazolam for the Prevention of Postoperative Nausea and Vomiting Caused by Hemabate in Cesarean Delivery: A Randomized Controlled Trial.
Hu B, Zhou H, Zou X, et al. · Drug Des Devel Ther 2020 · Comparative Study, Randomized Controlled Trial
- A prospective randomised trial to compare the efficacy and safety of hemabate and syntometrine for the prevention of primary postpartum haemorrhage.
Lamont RF, Morgan DJ, Logue M, et al. · Prostaglandins Other Lipid Mediat 2001 · Clinical Trial, Randomized Controlled Trial
- Efficacy and safety of motherwort injection add-on therapy to carboprost tromethamine for prevention of post-partum blood loss: A meta-analysis of randomized controlled trials.
Meng W, Li R, Zha N, et al. · J Obstet Gynaecol Res 2019 · Meta-Analysis, Review
- Controlling refractory atonic postpartum hemorrhage with Hemabate sterile solution.
Oleen MA, Mariano JP · Am J Obstet Gynecol 1990 · Clinical Trial, Multicenter Study
- Induction of abortion by intramuscular administration of (15S)-15-methyl PGF2 alpha. An overview of 815 cases.
Schwallie PC, Lamborn KR · J Reprod Med 1979 · Clinical Trial
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.